Skip to content

Spoton Trial Evaluating the Efficacy on BAlance Disorder sYmptoms (STEADY)

A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SpotOn Specs for the Treatment of Chronic Dizziness & Imbalance

Status
Suspended
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03726112
Acronym
STEADY
Enrollment
110
Registered
2018-10-31
Start date
2018-11-01
Completion date
2020-04-01
Last updated
2019-05-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Balance Disorders

Brief summary

A Randomized, Double Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of SpotOn specs for the Treatment of Chronic Dizziness & Imbalance.

Interventions

DEVICESpotOn Specs

SpotOn Balance glasses consists of unique visual stimuli (SpotOn's Neuro Balance Active Spots) applied to specific zones in the peripheral visual field

DEVICESham Specs

Sham device

Sponsors

SpotOn Therapeutics Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Intervention model description

A Randomized, Double Blind, Placebo-Controlled Study followed by an open label phase

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age: 18≤ years ≤70 * DHI score of at least 36 (moderate to severe handicap) * One or more symptoms of unsteadiness, dizziness or vertigo are present on most days. Symptoms could vary in intensity however lasts for 3 months or more * Ability to perform all tests (including computerized test) and interviews * At least three months after the last Vestibular Balanced Rehabilitation Therapy - (if applicable) * Gave informed consent for participation in the study

Exclusion criteria

* Dizziness disease with fluctuating symptoms * Any active or non-controlled disease that might cause dizziness and imbalance, unless well controlled for at least 3 months * Moderate-Severe Depression or Anxiety * Known related eye disease * Pregnant women * Currently taken part in a clinical trial or within 30 days prior to screening * Concomitant use of any medications that might affect the balance system

Design outcomes

Primary

MeasureTime frameDescription
Change from Baseline in the Dizziness Handicap Inventory (DHI)baseline, 8 weeksThe Dizziness Handicap Inventory (DHI) is a 25-item self-assessment scale. A yes response to an item is awarded 4 points, a sometimes 2 points, and a no, 0 points. Possible scores on the DHI range from 0 (suggesting no handicap) to 100, indicating significant perceived handicap

Secondary

MeasureTime frameDescription
Incident rate of falls8 weeksReported falls during the study
Clinical Global Impression of Improvement8 weeksThe Clinical Global Impression scale is a clinician-rated scale used to rate patients' improvement from baseline, based on the subject's baseline status- Improvement is rated on a scale of 1-7, with 1 being very much improved and 7 being very much worse
Change from baseline in the Clinical Global Impression of Severitybaseline, 8 weeksA clinician-rated scale used to rate patients' severity of symptoms. Severity is rated on a scale of 1-7 with one being normal, not at all ill, and 7 being among the most extremely ill patients.
Change from baseline in the Vertigo Symptom Scale-Short Form (VSS-SF)baseline, 8 weeksThe VSS assesses symptoms of balance system dysfunction (for example, dizziness, vertigo, postural instability, and falling) and symptoms of somatic anxiety and autonomic arousal (diverse pains and somatic sensations, sweating, pounding heart, breathing difficulties, and fainting). A measure of symptom severity is obtained by summing the item scores. The total scale score ranges 0-60, higher scores indicating more severe problems.
Change from baseline in the Visual Vertigo Analog Scale (VVAS)baseline, 8 weeksA visual analogue scale subjects are asked to evaluate their subjective feeling of dizziness in the last week on a scale from 0 (no dizziness at all) to 10 (very severe dizziness)
Change from baseline in the Beck Anxiety Inventorybaseline, 8 weeksA self-report inventory for measuring the severity of an individual's anxiety. The BAI contains 21 questions, each answer being scored on a scale value of 0 (not at all) to 3 (severely). Higher total scores indicate more severe anxiety symptoms.
Change from baseline in Postural swaybaseline, 8 weeksPostural control will be measure during stance and gait

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026